PET (positron emission tomography) is a powerful imaging technique that can provide quantitative information on the distribution of positron emitter labeled radiopharmaceuticals (PET radiopharmaceuticals) in the body. Positrons (ß+) are positively charged beta particles. They are emitted when the atom is proton rich. A positron has only a transient existence. After losing all of its kinetic ene...

PET (positron emission tomography) is a powerful imaging technique that can provide quantitative information on the distribution of positron emitter labeled radiopharmaceuticals (PET radiopharmaceuticals) in the body. Positrons (ß+) are positively charged beta particles. They are emitted when the atom is proton rich. A positron has only a transient existence. After losing all of its kinetic ene...

After reading Part IV of this series of nuclear cardiology articles, the reader should be able to describe: (a) the differences between SPECT and PET techniques; (b) the various radiopharmaceuticals and imaging protocols used for detecting viability with SPECT; (c) the different radiopharmaceuticals and imaging protocols used for detecting viability with PET; and (d) the imaging patterns observ...

One of the most common problems associated with radiopharmaceuticals is an unanticipated or altered biodistribution, which can have a significant clinical impact on safety, scan interpretation, and diagnostic imaging accuracy. In their most extreme manifestations, unanticipated imaging results may even compromise the utility and or accuracy of nuclear medicine studies. We present here an overal...

Pharmacokinetic (PK) studies of radiopharmaceuticals (RPs) are distinctive because small concentrations active ingredients. Whereas methods applicable to non-RP medicinal products cannot be used for RPs, radionuclide can provide an insight into behaviour. The aim the study was compare approaches pre-clinical PK evaluation RPs and other products. article describes main aspects non-RPs, defining ...